JHDAAI Team

Gerard Anderson is a professor of health policy and management and professor of international health at the Bloomberg School of Public Health, professor of medicine at the Johns Hopkins University School of Medicine, and director of the Johns Hopkins Center for Hospital Finance and Management.  He directs the JHDAAI and has published more than 300 peer-reviewed articles, testified in Congress more than 50 times as an individual witness, and serves on multiple editorial committees.  Prior to his arrival at Johns Hopkins, Anderson held various positions in the Office of the Secretary, U.S. Department of Health and Human Services, where he helped to develop Medicare prospective payment legislation.

ganderson@jhu.edu

Caleb Alexander is a professor of epidemiology and medicine at the Bloomberg School of Public Health, where he serves as founding co-director of the Center for Drug Safety and Effectiveness and Principal Investigator of the Johns Hopkins-FDA Center of Excellence in Regulatory Science and Innovation. He is a practicing general internist and pharmacoepidemiologist and is internationally recognized for his research examining prescription drug utilization, safety and effectiveness. The author of more than 375 scientific articles and book chapters, many of which have focused on the epidemiology of the opioid epidemic, he has published regularly in leading scientific journals and testified before expert bodies including the U.S. House of Representatives and U.S. Senate. Alexander also serves on several editorial and advisory boards and is a frequent speaker on pharmaceutical utilization and policy. He received his BA cum laude from the University of Pennsylvania, an MD from Case Western Reserve University, and an MS from the University of Chicago. Alexander’s research interests include prescription drugs; drug utilization; drug safety; drug effectiveness; pharmacoepidemiology, and pharmaceutical policy.

galexan9@jhmi.edu

Ge Bai is a professor of accounting at the Johns Hopkins Carey Business School and professor of health policy and management (joint) at the Bloomberg School of Public Health.  She is an expert on health care pricing, policy, and management.  Bai has written for the Wall Street Journal and published her studies in leading academic journals such as the New England Journal of Medicine, JAMA, Annals of Internal Medicine, and Health Affairs.  Her work has been widely featured in national media and used in government regulations and congressional testimony.  She is currently a visiting scholar at the Health Analysis Division of the Congressional Budget Office. Bai received her doctoral degree in Accounting from Michigan State University.

gbai@jhu.edu

Dr. Jeromie Ballreich is an Associate Research Professor and Director of the Master’s in Health Economics and Outcomes Research Program at the Johns Hopkins Bloomberg School of Public Health.  He is a health economist with a research focus on US pharmaceutical policy and economic evaluation. He has published in leading scientific journals and has testified before state legislators and the U.S. House of Representatives on pharmaceutical policy issues. He received his BA in Mathematics and Economics from Lafayette College, and a Masters and PhD in Health Economics from the Johns Hopkins Bloomberg School of Public Health.  Dr. Ballreich’s recent work has focused on pharmaceutical policy for cell and gene therapies; the intersection of drug prices, regulation, and innovation; and cost-effectiveness analyses alongside clinical trials.

Jeremy Greene is a professor of the history of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise includes internal medicine.  Greene serves as the Elizabeth Treide and A. McGehee Harvey Chair in the History of Medicine.  Greene’s research interests include the history of therapeutics, especially pharmaceuticals.  He also practices internal medicine at the East Baltimore Medical Center with admitting privileges to the Johns Hopkins University Hospital.  Greene earned his MD and PhD from Harvard University.  He completed his residency at Brigham & Women’s Hospital.  He serves on the Johns Hopkins University Press Faculty Editorial Board.  Greene’s research explores the ways in which medical technologies come to influence our understanding of what it means to be sick or healthy, normal or abnormal, on personal, regional, and global scales. Greene is the founding director of the Center for Medical Humanities and Social Medicine at Johns Hopkins University, Core Faculty in the JHDAAI, Associate Faculty at the Berman Institute of Bioethics, a co-Investigator in the Opioid Industry Documents Archive,  the Black Beyond Data Project, and the Sawyer Seminar in Precision and Uncertainty in a World of Data. He holds joint appointments in the Department of History of Science and Technology and the Department of Anthropology at the Krieger School of Arts and Sciences.

greene@jhmi.edu

Manuel Hermosilla is an associate professor of marketing at the Johns Hopkins Carey Business School. He is an applied microeconomist with expertise in drug innovation, drug consumption, clinical trials, and online pharmacies. Hermosilla’s research has been published in leading academic journals including Marketing Science, Management Science, and the Rand Journal of Economics. His work has been featured in national and international media outlets such as the New York Times, Vox, Axios, National Affairs, and the Hindustan Times. Hermosilla earned a PhD in Quantitative Marketing from the Kellogg School of Management at Northwestern University.

mh@jhu.edu

Joseph Levy is an assistant professor of health policy and management and a health economist who works on methods and policy to improve value-based decision making in healthcare.

jlevy@jhu.edu

Angela Liu is a PhD candidate in the Department of Health Policy and Management. As part of the JHDAAI team, she models alternative payment mechanisms for Medicare Part B drugs and examines potential cost-savings; studies beneficiary welfare implications of offering coupons to help pay for prescription drugs. She also compares biosimilar uptake under different forms of Medicare coverage, specifically Traditional Medicare and Medicare Advantage. Her dissertation examines the impact of prior authorization policies on physician-administered drug prescribing patterns and drug switching.

aliu63@jhu.edu

Jenny Markell is a PhD student at the Bloomberg School of Public Health in the Health Policy and Management department. Her research interests are in ensuring equitable access to health care and reducing health care costs for Americans, with a focus on pharmaceutical policy. She previously worked in the health care technology sector and in maternal and child health policy research. She received her BA from the University of Pennsylvania.

jmarkel4@jhu.edu

Ilina Odouard is a Research Associate in the Department of Health Policy and Management at the Bloomberg School of Public Health. Her research interests include influencing prescription drug and broader healthcare policy changes that promote affordability, access, and health equity through regulatory and payment reform. Her current research focuses on: 1) understanding how health care policies impact sociodemographic and geographic groups differently and the cost or access implications of those impacts; and 2) analyzing how clinical value is defined and connected to regulatory and payment decisions. She is a 2023 graduate of the BSPH MPH program. She previously worked in life sciences and health care strategy consulting primarily with pharmaceutical industry clients.

iodouar1@jhmi.edu

Joshua Sharfstein is the Vice Dean for Public Health Practice and Community Engagement at the Bloomberg School of Public Health. Sharfstein is also professor of the practice in the Department of Health Policy and Management.  Sharfstein was appointed by Governor Martin O’Malley as Secretary of the Maryland Department of Health and Mental Hygiene in January 2011. As Secretary of DHMH, Sharfstein led efforts to modernize Maryland’s all-payer system for hospital payment.  In March 2009, President Obama appointed Sharfstein to serve as the Principal Deputy Commissioner of the U.S. Food and Drug Administration, the agency’s second highest-ranking position. From December 2005 through March 2009, Sharfstein served as the Commissioner of Health for the City of Baltimore, Maryland.  He began working on health and social policy matters as an advisor to longtime California Congressman Henry A. Waxman.  Sharfstein also serves as a member of the editorial board at the Journal of the American Medical Association (JAMA). Sharfstein received his MD from Harvard Medical School.

joshua.sharfstein@jhu.edu

Mariana Socal is an assistant scientist in the Department of Health Policy and Management.  Socal studies ways to make the US pharmaceutical market more competitive, delivering drugs of greater value for lower costs to the American people.  Socal is a physician with training in clinical neurology.  She holds a master’s of public policy from Princeton University and a PhD in health systems from the Bloomberg School of Public Health.

msocal1@jhu.edu

Antonio Trujillo is an applied health economist known for his work on enhancing medication accessibility across the U.S., Latin America, and globally. He concentrates on strategies to bolster market competition, ultimately broadening access to affordable generic drugs and biosimilars.  Trujillo’s research delves into the intricate realm of antitrust issues, exploring phenomena such as "pay for delay" and “mergers” to decipher the underlying factors contributing to generic market inefficiencies. His work offers a framework for researchers using the concept of fair pricing as a cornerstone for innovative drug pricing policy.  Currently, he explores policies to remove barriers impeding brand-to-brand competition and seeks ways to expedite the introduction of biosimilars. Trujillo analyzes policies to promote adoption of green inhalers and other green medical devices. He is the director of the Master of Health Science in Global Health Economics program.

atrujil1@jhu.edu

Yang Wang is a research faculty in health economics and policy. His research interests include health care pricing and payment, health insurance market, and hospital finance.

ywang406@jhu.edu

Kiefer Ahn specializes in economic analysis to support litigation and complex business matters. As an intellectual property economist, he focuses on issues such as patent damages and antitrust in the pharmaceutical and life sciences industry.  Ahn has advised policymakers and business leaders on pharmaceutical drug pricing as well as forecasting cost projections.  He also conducts research on a wide range of topics related to intellectual property and healthcare markets.  He has served as an economist in the US Congress (Energy and Commerce Committee) and with the Johns Hopkins Drug Access and Affordability Initiative. He is actively engaged in academic research and publishes in peer-reviewed journals.
kiefer.ahn@nera.com

Kelly Anderson is an assistant professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences.  She is a health policy researcher who applies econometric and descriptive quantitative methods to examine the effects of health insurance design and to model policy options to improve payment for prescription drugs. In particular, her drug pricing research focuses on payment for Medicare Part B drugs, out-of-pocket costs for insulin, and branded competition. She also studies differences in the cost and quality of care between traditional Medicare and Medicare Advantage. Anderson received a PhD in Health Policy and Management from the Bloomberg School of Public Health, as well as Master of Public Policy and Bachelor of Science in Biomedical Engineering degrees from the University of Virginia.  She has also consulted for federal health care agencies, state legislatures, and private companies regarding insurance design and payment policy.

kelly.e.anderson@cuanschutz.edu

Charles Bennett is a hematologist and oncologist whose research focuses on preventing adverse drug events and improving drug safety. Bennett is studying ways to make drug information more consumer-friendly and creating new training tools for health care providers. Bennett has first-hand experience with commercializing technology and starting new companies. In 1998, he founded internationally known RADAR (Research on Adverse Drug Events And Reports) which investigates and disseminates information about adverse drug and device reactions (ADRs). His work has been awarded more than $4.2 million in federal research grants and has produced more than 250 publications. Bennett is currently affiliated with the Southern Network on Adverse Reactions (SONAR) which consists of co-investigators at fifty medical universities who have assisted with one or more evaluations of serious adverse drug reactions as part of two National Institutes of Health-funded pharmacovigilance grants.

bennettc@cop.sc.edu

Michael DiStefano is an assistant professor in the Center for Pharmaceutical Outcomes Research in the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado Anschutz Medical Campus. His research is primarily focused on health technology assessment, prescription drug policy, and direct-to-consumer pharmaceutical advertising. He is particularly interested in the ethical considerations that arise in each of these research areas. To advance research in these areas, DiStefano draws on both empirical research methods and conceptual and normative analysis. He completed his PhD in Health Policy & Management at the Bloomberg School of Public Health and also holds a master's degree in bioethics from the University of Pennsylvania.

michael.j.distefano@cuanschutz.edu

Jason Gibbons is an assistant professor at the University of Colorado Anschutz Medical Campus in the Department of Health Systems, Management and Policy.   His primary research interests include prescription drug utilization, effectiveness, and adherence, especially regarding mental health and substance use disorders.  He is also interested in issues related to drug pricing policy, patient spending on pharmaceuticals, and pharmaceutical antitrust.  Gibbons previously worked for the Bloomberg Overdose Prevention Initiative at Johns Hopkins University as a Postdoctoral Fellow to conduct program and policy evaluations to expand Medication for Opioid Use Disorder access, use, and equity.  He received his PhD in Health Services Organization and Policy (Economics Cognate) at the University of Michigan School of Public Health.

jason.gibbons@cuanschutz.edu

So Yeon Kang is an assistant professor of health management and policy at the Georgetown School of Health. Her research focuses on issues at the intersection of health care payment policy, innovations, and business management. Her current research portfolio centers around prescription drug pricing policy, access and affordability and care delivery innovations under value-based payment reform. Kang’s research has been published in JAMA and Health Affairs and has been featured in media outlets including Forbes and Reuters. Prior to coming to academia, Kang gained experience in the pharmaceutical industry, having held positions in pricing and health technology assessment. Kang holds a PhD and an MBA from Johns Hopkins University.

sk2327@georgetown.edu

Joey Mattingly has been in pharmacy for more than twenty years, with pharmacy operations experience as an entry-level technician, staff pharmacist, pharmacy manager, district manager for a major pharmacy chain, and private equity start-up director for a long-term care pharmacy operation serving multiple states. Mattingly left the private sector in 2014 to pursue an academic career while simultaneously earning his PhD in Health Services Research with a specific focus on pharmacoeconomics. Since 2014, Mattingly has developed a research portfolio that primarily focuses on drug pricing policy, and he has engaged policymakers at local, state, and federal levels, including serving as Speaker of the House of Delegates and Trustee for the American Pharmacists Association (APhA) from 2019‒2021. From November 2022 to April 2023, Mattingly served as an advisor to the Center of Medicare and Medicaid Services (CMS) to aid in the implementation of the new “Drug Price Negotiation Program” authorized by Congress through the Inflation Reduction Act. Most recently, he was named a Research Fellow for the National Association of Insurance Commissioners (NAIC) to help inform policy on pharmacy benefit manager practices.

joey.mattingly@pharm.utah.edu

Thomas Moore is senior scientist, drug safety and policy, at the Institute for Safe Medication Practices. He has spent more than a decade as a researcher, writer and lecturer on the risks and benefits of prescription drugs. He is the author of four books about medical care, including two examining the nation's system for minimizing the dangers of prescription drugs. Deadly Medicine (Simon & Schuster, 1995) was an investigation of the nation's worst drug disaster in which tens of thousands of heart patients died from the inappropriate use of drugs for irregular heartbeats. Prescription for Disaster (Simon & Schuster, 1998) sounded the alarm about the nation's failure to take adequate measures to minimize the risks of prescription drugs. He is also author of numerous articles about medication error and drug safety for peer-reviewed scientific journals as well as articles for the general public. Prior to focusing on drug policy issues, he was a prize-winning investigative reporter in Washington and worked on the U.S. Senate staff.

tmoore86@jhmi.edu

Robin Dranbauer is a Senior Administrative Coordinator within the department of Health Policy and Management. She manages administrative and financial tasks associated with JHDAAI.
rdranba1@jhu.edu

Michele Trieb is a Senior Program Manager within the department of Health Policy and Management. She manages, coordinates, and facilitates data analytic projects and tasks for JHDAAI. She also maintains this website.
mtrieb2@jhu.edu